|
Bioactive compounds
(Clinicaltrials.gov identifier) | Disease condition | Phase | Dosage | Study goal |
|
Quercetin
(NCT03476330) | Squamous cell carcinoma | II | 4 g/day | Efficacy in reducing buccal micronuclei in patients with Fanconi anemia |
Curcumin
(NCT03769766) | Prostate cancer | III | 500 mg, 2x/day | Effect on prostate cancer progression |
| (NCT00094445) | Pancreatic cancer | II | 8 g/day | Effect in pancreatic cancer growth and the safety of treatment |
| (NCT01246973) | Radiation dermatitis | III | 500 mg, 3x/day | Effect on dermatitis caused by radiation therapy in breast cancer patients |
With piperine
(NCT02598726) | Neoplasms | I | A dose escalation study | Optimal biological dose in cancer patients |
Capsaicin
(NCT02037464) | Prostate cancer | II | 2 capsules/day for 6 months | Expression of Ki67 and p27 in a posttreatment biopsy |
| (NCT00003610) | Head & neck cancer, mucositis | III | 4 lozenges/day up to 2 weeks after radiation therapy | Efficacy of lozenges in patients with mucositis caused by radiation therapy |
| Patch (Qutenza) (NCT03317613) | Cancer | II | Qutenza (8% capsaicin patch) for every 3 months | Efficacy in peripheric neuropathic pain in cancer patients |
EGCG
(NCT02891538) | Colon cancer | Early I | 450 mg, 2x/day | Chemopreventive effects |
| (NCT01317953) | Small cell lung carcinoma | I | to | Side effects and best dose |
PEITC
(NCT00691132) | Lung cancer | II | 4x/day for 5 days in week 4 | Effect in preventing lung cancer in smokers |
| (NCT01790204) | Oral cancer | I & II | | Effect on oral cells with mutant p53 |
Nutri-PEITC jelly
(NCT03034603) | Head & neck neoplasms | | 200 mg/day, 5 days/week for 3 months | Safety and efficacy |
Resveratrol
(NCT00256334) | Colon cancer | I | 20 mg/day | Modulation of Wnt signalling in vivo |
| (NCT01476592) | Neuroendocrine tumor | | 5 g/day | Effect on Notch-1 signalling |
SRT501
(NCT00920803) | Colorectal cancer | I | 5 g/day | Safety and tolerability |
|
